Prevalence and Characteristics of Hepatic Hemangioma Associated with Coagulopathy and Its Predictive Risk Factors
- PMID: 35893437
- PMCID: PMC9368925
- DOI: 10.3390/jcm11154347
Prevalence and Characteristics of Hepatic Hemangioma Associated with Coagulopathy and Its Predictive Risk Factors
Abstract
Background: Knowledge of the relationships between hepatic hemangiomas and coagulopathy and the risk factors for hemangiomas is lacking. The aim of this study was to investigate the prevalence and characteristics of hepatic hemangiomas associated with coagulopathy, elucidate the causes of coagulopathy, and identify the predictive factors for hemangioma-related complications. Methods: In 281 consecutive patients with hepatic hemangiomas, we performed ultrasonography and conducted serum laboratory tests for liver function and six coagulation factors, i.e., platelets, as well as five coagulation fibrinolytic markers (prothrombin time (PT), fibrinogen, thrombin-antithrombin III complex (TAT), d-dimer, and fibrin and fibrinogen degradation products (FDP)) as indicators of coagulation disorder. Results: Among 281 patients, 56 (19.9%) had abnormal coagulation factors. Abnormal values of d-dimer were most frequently found among the six coagulation factors. The number of abnormal coagulation factors was significantly correlated with tumor size, M2BPGi, and HDL cholesterol, among which tumor size was the most significant independent predictor of the number of abnormal coagulation factors. Conclusions: The prevalence of hepatic hemangiomas associated with coagulopathy was relatively high and became more frequent with increases in tumor size. Predictive factors of hemangioma-related complications were found to be a tumor size of >5 cm in diameter and coagulopathy, especially the elevation of d-dimer.
Keywords: coagulation factor; coagulopathy; hemangioma-related complication; hepatic hemangioma.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Elevated Serum Protein Induced by Vitamin K Absence or Antagonist II Levels in Patients with Hepatic Hemangiomas.Int J Mol Sci. 2025 Apr 13;26(8):3681. doi: 10.3390/ijms26083681. Int J Mol Sci. 2025. PMID: 40332214 Free PMC article.
-
The Natural History and Management of Hepatic Hemangioma.J Clin Med. 2023 Sep 1;12(17):5703. doi: 10.3390/jcm12175703. J Clin Med. 2023. PMID: 37685768 Free PMC article.
-
Association of tumor size and internal echo pattern with coagulopathy associated with hepatic hemangioma.Mol Clin Oncol. 2021 Apr;14(4):83. doi: 10.3892/mco.2021.2245. Epub 2021 Feb 26. Mol Clin Oncol. 2021. PMID: 33758664 Free PMC article.
-
[A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].Rinsho Byori. 2004 Apr;52(4):355-61. Rinsho Byori. 2004. PMID: 15164605 Review. Japanese.
-
Liver Transplantation for Giant Hemangioma Complicated by Kasabach-Merritt Syndrome: A Case Report and Literature Review.Am J Case Rep. 2022 May 23;23:e936042. doi: 10.12659/AJCR.936042. Am J Case Rep. 2022. PMID: 35796001 Free PMC article. Review.
Cited by
-
A novel classifier combining G protein-coupled receptors and the tumor microenvironment is associated with survival status in glioblastoma.Front Pharmacol. 2023 Jul 25;14:1093263. doi: 10.3389/fphar.2023.1093263. eCollection 2023. Front Pharmacol. 2023. PMID: 37560473 Free PMC article.
-
Elevated Serum Protein Induced by Vitamin K Absence or Antagonist II Levels in Patients with Hepatic Hemangiomas.Int J Mol Sci. 2025 Apr 13;26(8):3681. doi: 10.3390/ijms26083681. Int J Mol Sci. 2025. PMID: 40332214 Free PMC article.
-
Reconsideration of the clinical management of hepatic hemangioma.World J Gastrointest Surg. 2024 Nov 27;16(11):3623-3628. doi: 10.4240/wjgs.v16.i11.3623. World J Gastrointest Surg. 2024. PMID: 39649192 Free PMC article.
-
The Natural History and Management of Hepatic Hemangioma.J Clin Med. 2023 Sep 1;12(17):5703. doi: 10.3390/jcm12175703. J Clin Med. 2023. PMID: 37685768 Free PMC article.
References
-
- Isidori D.C., Renol K., Saif A.M., Annalisa A., Gaetano B., Adriana T. Giant carvenous liver hemangiomas: Is it the time to change the size categories? Hepatobiliary Pancreat Dis. Int. 2016;15:21–29. - PubMed
-
- Paulo H., Marcelo L.V.C., Marcel A.C.M., Vincenzo P., Luis A.C.D., Marcel C.C.M., Joaquim J.G.R., William A.S. Management of hepatic hemangiomas: A 14-year experience. J. Gastrointest. Surg. 2005;9:853–859. - PubMed
-
- Li J., Huang L., Liu C., Yan J., Xu F., Wu M., Yan Y. New recognition of the natural history and growth pattern of hepatic hemangioma in adults. Hepatol. Res. 2016;46:727–733. - PubMed
LinkOut - more resources
Full Text Sources